NBT Bank N A NY reduced its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 1.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 118,538 shares of the biopharmaceutical company’s stock after selling 1,384 shares during the quarter. Bristol-Myers Squibb comprises 1.2% of NBT Bank N A NY’s portfolio, making the stock its 25th biggest position. NBT Bank N A NY’s holdings in Bristol-Myers Squibb were worth $7,556,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Bristol-Myers Squibb by 0.3% during the 2nd quarter. Vanguard Group Inc. now owns 118,661,690 shares of the biopharmaceutical company’s stock valued at $6,611,829,000 after purchasing an additional 333,685 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Bristol-Myers Squibb by 2.4% during the 2nd quarter. BlackRock Inc. now owns 99,454,602 shares of the biopharmaceutical company’s stock valued at $5,541,612,000 after purchasing an additional 2,367,864 shares in the last quarter. Dodge & Cox lifted its holdings in shares of Bristol-Myers Squibb by 1.6% during the 2nd quarter. Dodge & Cox now owns 29,579,461 shares of the biopharmaceutical company’s stock valued at $1,648,168,000 after purchasing an additional 459,271 shares in the last quarter. Jennison Associates LLC lifted its holdings in shares of Bristol-Myers Squibb by 16.2% during the 3rd quarter. Jennison Associates LLC now owns 26,854,242 shares of the biopharmaceutical company’s stock valued at $1,711,689,000 after purchasing an additional 3,735,453 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in shares of Bristol-Myers Squibb by 3.9% during the 2nd quarter. Northern Trust Corp now owns 24,041,862 shares of the biopharmaceutical company’s stock valued at $1,339,612,000 after purchasing an additional 910,496 shares in the last quarter. Institutional investors own 69.74% of the company’s stock.

In related news, Director Theodore R. Samuels II acquired 4,000 shares of the company’s stock in a transaction dated Friday, December 15th. The shares were bought at an average price of $62.30 per share, for a total transaction of $249,200.00. Following the purchase, the director now directly owns 22,000 shares in the company, valued at approximately $1,370,600. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the company’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total value of $335,172.00. Following the sale, the executive vice president now owns 9,251 shares in the company, valued at approximately $585,033.24. The disclosure for this sale can be found here. Insiders own 0.23% of the company’s stock.

BMY has been the topic of several recent analyst reports. Cowen reiterated a “hold” rating and set a $65.00 price objective on shares of Bristol-Myers Squibb in a report on Tuesday, September 19th. Vetr upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $66.50 price objective on the stock in a report on Wednesday, September 27th. Jefferies Group reiterated a “buy” rating and set a $72.00 price objective on shares of Bristol-Myers Squibb in a report on Wednesday, September 27th. UBS Group reiterated a “buy” rating and set a $72.00 price objective (up previously from $62.00) on shares of Bristol-Myers Squibb in a report on Friday, October 6th. Finally, BMO Capital Markets set a $49.00 price objective on Bristol-Myers Squibb and gave the company a “sell” rating in a report on Thursday, October 12th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the stock. Bristol-Myers Squibb has an average rating of “Hold” and an average price target of $65.11.

Shares of Bristol-Myers Squibb Co (NYSE BMY) opened at $59.92 on Wednesday. The company has a market capitalization of $98,070.00, a P/E ratio of 23.59, a price-to-earnings-growth ratio of 2.30 and a beta of 1.18. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46. Bristol-Myers Squibb Co has a 12 month low of $46.01 and a 12 month high of $66.10.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). The firm had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The company’s revenue was up 6.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.77 EPS. equities research analysts expect that Bristol-Myers Squibb Co will post 2.99 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, February 1st. Shareholders of record on Friday, January 5th will be paid a $0.40 dividend. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Thursday, January 4th. This represents a $1.60 annualized dividend and a yield of 2.67%. Bristol-Myers Squibb’s payout ratio is presently 62.99%.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/01/17/nbt-bank-n-a-ny-has-7-56-million-stake-in-bristol-myers-squibb-co-bmy.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related stocks with our FREE daily email newsletter.